| Literature DB >> 31316713 |
Abstract
BACKGROUND: Cross-reactivity between pollen and plant foods results in low specificity of food-IgE and skin prick testing, which may cause over-diagnosis. A test that can accurately diagnose pollen-related food allergy and identify patients at risk of developing severe reactions is needed. This study evaluates basophil CD63 expression as a biomarker for diagnosis and predicting severity of mugwort pollen-related peach allergy.Entities:
Keywords: AUC, area under the curve; BAT, basophil activation test; Basophil activation test; DBPCFC, double-blind placebo-controlled food challenge; LTP, lipid transfer protein; Mugwort pollen allergy; OAS, oral allergy syndrome; Peach allergy; Peach extract; Pru p 3; ROC, receiver operating characteristic; SABA, short-acting β2-agonist; SPT, skin prick testing; SR, systemic reaction; sIgE, specific IgE
Year: 2019 PMID: 31316713 PMCID: PMC6593310 DOI: 10.1016/j.waojou.2019.100043
Source DB: PubMed Journal: World Allergy Organ J ISSN: 1939-4551 Impact factor: 4.084
Demographic and molecule sensitization profiles of participants.
| Characteristic | MPRPA (n = 38) | Peach tolerant (n = 31) | ||
|---|---|---|---|---|
| PST (n = 21) | NSE (n = 10) | |||
| Age (y) | 22 (11–52) | 29 (13–58) | 27 (18–42) | .37 |
| Males | 20 (52.6) | 9 (42.9) | 4 (40) | .06 |
| tIgE | 232.5 (19–1810) | 241.5 (39–1462) | 72 (38–152) | .85 |
| sIgE | ||||
| Peach | 11.2 (0.57–100) | 3.46 (0.38–38.5) | 0.01 (0–0.08) | |
| Pru p 1 | 0.01 (0–25.1) | 0.01 (0–5.2) | 0.01 (0–0.02) | .65 |
| Pru p 3 | 8.64 (0.03–78.2) | 0.85 (0–32.7) | 0.01 (0–0.03) | |
| Pru p 4 | 0.01 (0–32.7) | 0.01 (0–15.6) | 0.01 (0–0.02) | .81 |
Values are expressed as median (range) or numbers (percentages).
MPRPA, mugwort pollen-related peach-allergic patients; PST, peach-sensitized but tolerant patients; NSE, non-peach-sensitized nonallergic patients.
P value refers to the comparison between MPRPA and PST patients.
Demographic and clinical features of the study population according to severity groups.
| Peach allergy (n = 38) | |||
|---|---|---|---|
| OAS (n = 15) | SR (n = 23) | ||
| Age (y) | 19 (11–47) | 28 (6–51) | .25 |
| Males | 9 (60) | 11 (47.8) | .52 |
| tIgE | 257 (21–1720) | 326 (30–1421) | .89 |
| sIgE | |||
| Peach | 9.7 (0.68–100) | 11.8 (1.2–50.3) | .27 |
| Pru p 1 | 0.01 (0–25.8) | 0.01 (0–16.9) | .43 |
| Pru p 3 | 6.8 (0.03–45.6) | 11.3 (0.04–78.2) | |
| Pru p 4 | 0 (0–45.2) | 0.02 (0–18.4) | .91 |
| Mugwort pollen allergy | |||
| Ocular symptoms | 12 (80) | 18 (78.3) | .90 |
| Nasal symptoms | 15 (100) | 21 (91.3) | ND |
| Asthma | 5 (33.3) | 15 (65.2) | .052 |
| Asthma treatment | |||
| SABAs | 1 (6.7) | 8 (34.8) | |
| Management in ED | 0 | 2 (8.7) | ND |
Values are expressed as medians (range) or numbers (percentages).
OAS, oral allergy syndrome; SR, systemic reaction; SABAs, short-acting β2-agonists; ED, emergency department; ND, not different.
Fig. 1BAT upon stimulation with peach extract (1 ng/mL–10 μg/mL) and Pru p 3 (25 ng/mL) in mugwort pollen-related peach-allergic (MPRPA, n = 38), peach-sensitized but tolerant (PST, n = 21) and non-peach-sensitized nonallergic group (NSE, n = 10) patients. **P < .001.
Fig. 2BAT at different doses of peach extract (1 ng/mL–10 μg/mL) and Pru p 3 (25 ng/mL) in OAS (n = 15) versus SR (n = 23) groups. **P < .001. OAS, oral allergy syndrome; SR, systemic reaction.
Fig. 3ROC curve analysis for specific IgE, component testing and BAT in predicting peach allergy. BAT stimulated with 25 ng/mL Pru p 3 had the largest area under ROC curve (AUC 0.96, 95% CI 0.916–1.000, P < .001) compared with BAT at 100 ng/mL peach (AUC 0.90, 95% CI 0.804–0.997, P < .001), specific IgE to peach (AUC 0.73, 95% CI 0.592–0.873, P = .005), and specific IgE to Pru p 3 (AUC 0.81, 95% CI 0.690–0.932, P < .001). AUC, the area under curve; CI, confidence interval.
Optimal cutoffs for peach-sIgE, Pru p 3-sIgE and BAT to peach and Pru p 3 with the largest area under the ROC curve in predicting peach allergy.
| Cutoff | AUC | Sensitivity | Specificity | PPV | NPV | LR+ | LR- | |
|---|---|---|---|---|---|---|---|---|
| Peach-sIgE | 4.06 | 0.73 | 76.9% | 66.7% | 71.4% | 72.7% | 2.3 | 0.3 |
| Pru p 3- sIgE | 0.64 | 0.81 | 92.3% | 66.7% | 76.5% | 87.5% | 3 | 0.1 |
| % CD63+ (peach) | 19.4 | 0.90 | 100% | 86.3% | 81.3% | 100% | 7.3 | – |
| % CD63+ (Pru p 3) | 13.0 | 0.96 | 92.3% | 94.6% | 92.3% | 91.7% | 17.1 | 0.08 |
ROC, receiver operating characteristic; AUC, area under the ROC curve; PPV, positive predictive value; NPV, negative predictive value; LR+, positive likelihood ratio; LR-, negative likelihood ratio; % CD63+, percentage of CD63-positive basophils.
Fig. 4ROC curve analysis for specific IgE to peach and its allergenic components and BAT in predicting systemic reactions to peach. BAT stimulated with 25 ng/mL Pru p 3 had the largest area under ROC curve (AUC 0.90, 95% CI 0.762–1.000, P = .001) compared with BAT at 100 ng/mL peach (AUC 0.71, 95% CI 0.511–0.900, P = .08), and specific IgE to Pru p 3 (AUC 0.73, 95% CI 0.534–0.921, P = .049). AUC, the area under curve; CI, confidence interval.